184 related articles for article (PubMed ID: 33823362)
1. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
Zichi C; Paratore C; Gargiulo P; Mariniello A; Reale ML; Audisio M; Bungaro M; Caglio A; Gamba T; Perrone F; Di Maio M
Eur J Cancer; 2021 May; 149():49-60. PubMed ID: 33823362
[TBL] [Abstract][Full Text] [Related]
2. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
Llovet JM; Montal R; Villanueva A
J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
[TBL] [Abstract][Full Text] [Related]
3. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
4. Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non-Small Cell Lung Cancer.
Ikeda M; Ochibe T; Tohkin M
Ther Innov Regul Sci; 2019 May; 53(3):324-331. PubMed ID: 30089401
[TBL] [Abstract][Full Text] [Related]
5. Subgroup analyses in randomized phase III trials of systemic treatments in patients with advanced solid tumours: a systematic review of trials published between 2017 and 2020.
Paratore C; Zichi C; Audisio M; Bungaro M; Caglio A; Di Liello R; Gamba T; Gargiulo P; Mariniello A; Reale ML; Perrone F; Di Maio M
ESMO Open; 2022 Dec; 7(6):100593. PubMed ID: 36228332
[TBL] [Abstract][Full Text] [Related]
6. Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials.
Pasalic D; McGinnis GJ; Fuller CD; Grossberg AJ; Verma V; Mainwaring W; Miller AB; Lin TA; Jethanandani A; Espinoza AF; Diefenhardt M; Das P; Subbiah V; Subbiah IM; Jagsi R; Garden AS; Fokas E; Rödel C; Thomas CR; Minsky BD; Ludmir EB
Eur J Cancer; 2020 Sep; 136():176-185. PubMed ID: 32702645
[TBL] [Abstract][Full Text] [Related]
7. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour.
Zhang J; Zhang Y; Tang S; Jiang L; He Q; Hamblin LT; He J; Xu Z; Wu J; Chen Y; Liang H; Chen D; Huang Y; Wang X; Deng K; Jiang S; Zhou J; Xu J; Chen X; Liang W; He J
BMJ Open; 2018 Sep; 8(9):e017240. PubMed ID: 30206071
[TBL] [Abstract][Full Text] [Related]
8. Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA; Pulido M; Gourgou S; Collette L; Doussau A; Kramar A; Dabakuyo TS; Ouali M; Auperin A; Filleron T; Fortpied C; Le Tourneau C; Paoletti X; Mauer M; Mathoulin-Pélissier S; Bonnetain F
Eur J Cancer; 2013 Mar; 49(4):769-81. PubMed ID: 23122780
[TBL] [Abstract][Full Text] [Related]
9. Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.
Reale ML; De Luca E; Lombardi P; Marandino L; Zichi C; Pignataro D; Ghisoni E; Di Stefano RF; Mariniello A; Trevisi E; Leone G; Muratori L; La Salvia A; Sonetto C; Bironzo P; Aglietta M; Novello S; Scagliotti GV; Perrone F; Di Maio M
Lung Cancer; 2020 Jan; 139():47-54. PubMed ID: 31734586
[TBL] [Abstract][Full Text] [Related]
10. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
11. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review.
Mohyuddin GR; Koehn K; Abdallah AO; W Sborov D; Rajkumar SV; Kumar S; McClune B
Am J Hematol; 2021 Jun; 96(6):690-697. PubMed ID: 33735453
[TBL] [Abstract][Full Text] [Related]
12. Sample size determination for the current strategy in oncology Phase 3 trials that tests progression-free survival and overall survival in a two-stage design framework.
Nomura S; Hirakawa A; Hamada C
J Biopharm Stat; 2018; 28(4):589-611. PubMed ID: 28886305
[TBL] [Abstract][Full Text] [Related]
13. Resampling phase III data to assess phase II trial designs and endpoints.
Sharma MR; Karrison TG; Jin Y; Bies RR; Maitland ML; Stadler WM; Ratain MJ
Clin Cancer Res; 2012 Apr; 18(8):2309-15. PubMed ID: 22287601
[TBL] [Abstract][Full Text] [Related]
14. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Pilz LR; Manegold C; Schmid-Bindert G
Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
[TBL] [Abstract][Full Text] [Related]
15. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
16. An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.
Conde-Estévez D; Tusquets I; Servitja S; Martínez-García M; Salas E; Albanell J
Anticancer Drugs; 2014 Oct; 25(9):992-7. PubMed ID: 24892723
[TBL] [Abstract][Full Text] [Related]
17. Trends in endpoint selection in clinical trials of advanced breast cancer.
Song SY; Seo H; Kim G; Kim AR; Kim EY
J Cancer Res Clin Oncol; 2016 Nov; 142(11):2403-13. PubMed ID: 27586374
[TBL] [Abstract][Full Text] [Related]
18. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
19. Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study.
Fernández-López C; Calleja-Hernández MÁ; Balbino JE; Cabeza-Barrera J; Expósito-Hernández J
Thorac Cancer; 2019 Apr; 10(4):904-908. PubMed ID: 30868737
[TBL] [Abstract][Full Text] [Related]
20. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
